Company raises $55M to advance therapies for celiac, other autoimmune disorders
Biotech company Mozart Therapeutics has raised $55 million in Series A funding.
Mozart is targeting autoimmune and inflammatory diseases through a network of what are called CD8 regulatory T cells. The work is built on the research of T cell biology expert Mark M. Davis. Mozart said the Series A will help the company to progress its treatment to the clinic while advancing oth er programs as well.
"Mozart is doing something truly unique to change the treatment paradigm for patients with autoimmune…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Rick Morgan Source Type: news
More News: Autoimmune Disease | Biology | Biotechnology | Celiac Disease | Coeliac Disease | Cytology | Funding | Health Management | Pharmaceuticals